Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H22N4O3 |
| Molecular Weight | 378.4244 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=NC=C(C)C2=C1[C@H](C3=CC=C(C=C3OC)C#N)C(C(N)=O)=C(C)N2
InChI
InChIKey=BTBHLEZXCOBLCY-QGZVFWFLSA-N
InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
FINERENONE is a potent and selective nonsteroidal mineralocorticoid receptor antagonist. Results in preclinical studies showed that lower doses of FINERENONE were needed to achieve similar cardiorenal protective effects compared to both spironolactone and eplerenone. It is in phase III clinical trials for the treatment of diabetic kidney disease.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. | 2012 Aug |
|
| Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. | 2012 Sep 27 |
|
| Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. | 2013 Aug |
|
| Renin-angiotensin system blockade: Finerenone. | 2017 Apr |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID10146928
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY | |||
|
BC-45
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY | |||
|
C169981
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY | |||
|
1050477-31-0
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY | |||
|
Finerenone
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY | |||
|
CHEMBL2181927
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY | |||
|
100000169992
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY | |||
|
9634
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY | |||
|
60150535
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY | |||
|
DE2O63YV8R
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY | |||
|
SUB183743
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY | |||
|
2562811
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY | |||
|
DE2O63YV8R
Created by
admin on Sat Dec 16 05:41:51 GMT 2023 , Edited by admin on Sat Dec 16 05:41:51 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
